Title : Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Pub. Date : 2018 Jul 10

PMID : 29986854






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Finally, we assessed the efficacy of JAK3 inhibition and showed that CTCL JAK3A572V-positive T cells are sensitive to tofacitinib, which provides additional preclinical insights into the use of JAK3 inhibitors in these disorders. tofacitinib Janus kinase 3 Mus musculus
2 Finally, we assessed the efficacy of JAK3 inhibition and showed that CTCL JAK3A572V-positive T cells are sensitive to tofacitinib, which provides additional preclinical insights into the use of JAK3 inhibitors in these disorders. tofacitinib Janus kinase 3 Mus musculus